NYSE:PFE - Pfizer Stock Price, News, & Analysis

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Pfizer announced a quarterly dividend on Thursday, June 28th. Stockholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.09%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

Pfizer announced that its board has approved a share repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's leadership believes its shares are undervalued.

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. The biopharmaceutical company had revenue of $13.47 billion for the quarter, compared to analysts' expectations of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm's quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 EPS. View Pfizer's Earnings History.

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

Pfizer updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

20 equities research analysts have issued 1 year price targets for Pfizer's shares. Their forecasts range from $37.00 to $47.00. On average, they expect Pfizer's share price to reach $42.1765 in the next twelve months. This suggests that the stock has a possible downside of 4.3%. View Analyst Price Targets for Pfizer.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Pfizer saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 48,507,825 shares, a decrease of 7.1% from the August 15th total of 52,192,249 shares. Based on an average trading volume of 18,845,697 shares, the short-interest ratio is presently 2.6 days. Currently, 0.8% of the company's stock are sold short. View Pfizer's Current Options Chain.

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bayer (BAYRY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Pfizer's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), Northern Trust Corp (1.28%), Bank of New York Mellon Corp (1.14%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%) and Morgan Stanley (0.91%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

PFE stock was purchased by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Royal London Asset Management Ltd., Natixis and Fisher Asset Management LLC. View Insider Buying and Selling for Pfizer.

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PFE stock can currently be purchased for approximately $44.06.

Pfizer has a market capitalization of $260.44 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

The official website for Pfizer is http://www.pfizer.com.

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.